<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39421951</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>42</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title><ISOAbbreviation>Euro Surveill</ISOAbbreviation></Journal><ArticleTitle>Sweden surpasses the UNAIDS 95-95-95 target: estimating HIV-1 incidence, 2003 to 2022.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2400058</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2807/1560-7917.ES.2024.29.42.2400058</ELocationID><Abstract><AbstractText>BackgroundSweden reached the UNAIDS 90-90-90 target in 2015. It is important to reassess the HIV epidemiological situation due to ever-changing migration patterns, the roll-out of PrEP and the impact of the COVID-19 pandemic.AimWe aimed to assess the progress towards the UNAIDS 95-95-95 targets in Sweden by estimating the proportion of undiagnosed people with HIV (PWHIV) and HIV incidence trends.MethodsWe used routine laboratory data to inform a biomarker model of time since infection. When available, we used previous negative test dates, arrival dates for PWHIV from abroad and transmission modes to inform our incidence model. We also used data collected from the Swedish InfCareHIV register on antiretroviral therapy (ART).ResultsThe yearly incidence of HIV in Sweden decreased after 2014. In part, this was because the fraction of undiagnosed PWHIV had decreased almost twofold since 2006. After 2015, three of four PWHIV in Sweden were diagnosed within 1.9 and 3.2 years after infection among men who have sex with men and in heterosexual groups, respectively. While 80% of new PWHIV in Sweden acquired HIV before immigration, they make up 50% of the current PWHIV in Sweden. By 2022, 96% of all PWHIV in Sweden had been diagnosed, and 99% of them were on ART, with 98% virally suppressed.ConclusionsBy 2022, about half of all PWHIV in Sweden acquired HIV abroad. Using our new biomarker model, we assess that Sweden has reached the UNAIDS goal at 96-99-98.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lundgren</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>These authors contributed equally to this work and share first authorship.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Theoretical Biology &amp; Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locke</LastName><ForeName>Macauley</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>These authors contributed equally to this work and share first authorship.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Theoretical Biology &amp; Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-Severson</LastName><ForeName>Ethan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Theoretical Biology &amp; Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitrijevic</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Theoretical Biology &amp; Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelsson</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Public Health Agency of Sweden, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Emmi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Agency of Sweden, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlander</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brännström</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Science and Education (KISÖS), Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Södersjukhuset, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norrgren</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences Lund, Division of Infection Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansson</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, Clinical Infection Medicine, Lund University, Malmö, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elvstam</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Växjö Central Hospital, Växjö, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine, Clinical Infection Medicine, Lund University, Malmö, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gisslén</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Region Västra Götaland, Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Agency of Sweden, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fohlin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Region Jämtland Härjedalen, Östersund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sönnerborg</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leitner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Theoretical Biology &amp; Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI152897</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Euro Surveill</MedlineTA><NlmUniqueID>100887452</NlmUniqueID><ISSNLinking>1025-496X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018451" MajorTopicYN="N">Homosexuality, Male</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">UNAIDS</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">modelling</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> JB has received research grants from Gilead Sciences and honoraria as scientific advisor from Gilead Sciences, GlaxoSmithKline/ViiV, and MSD, all outside the scope of this project; MG has received research grants from Gilead Sciences and honoraria as speaker, DSMB committee member and/or scientific advisor from Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen-Cilag, MSD, Novocure, Novo Nordic, Pfizer and Sanofi, all outside the scope of this project; CC has received research grants from Gilead Sciences and honorarias as speaker and scientific advisor from Gilead Sciences, GlaxoSmithKline/ViiV, and MSD, all outside the scope of this project; OE has received honoraria as speaker from Gilead Sciences, unrelated to this work. All other authors none.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39421951</ArticleId><ArticleId IdType="pmc">PMC11487918</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.42.2400058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Joint United Nations Programme on HIV/AIDS (UNAIDS). The path that ends AIDS: UNAIDS Global AIDS Update 2023. Geneva: UNAIDS; 2023. Available from: https://thepath.unaids.org/wp-content/themes/unaids2023/assets/files/2023_report.pdf
</Citation></Reference><Reference><Citation>Trickey A, Sabin CA, Burkholder G, Crane H, d’Arminio Monforte A, Egger M, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295-307. 10.1016/S2352-3018(23)00028-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(23)00028-0</ArticleId><ArticleId IdType="pmc">PMC10288029</ArticleId><ArticleId IdType="pubmed">36958365</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan AK, Raben D, Reekie J, Rayment M, Mocroft A, Esser S, et al. Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One. 2013;8(1):e52845. 10.1371/journal.pone.0052845</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052845</ArticleId><ArticleId IdType="pmc">PMC3546115</ArticleId><ArticleId IdType="pubmed">23341910</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint United Nations Programme on HIV/AIDS (UNAIDS). Undetectable = untransmittable. Public health and hiv viral load suppression. Geneva: UNAIDS; 2018. Available from: https://www.unaids.org/en/resources/presscentre/featurestories/2018/july/undetectable-untransmittable
</Citation></Reference><Reference><Citation>Working Group on Estimation of HIV Prevalence in Europe . HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. AIDS. 2011;25(8):1017-23. 10.1097/QAD.0b013e3283467087</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e3283467087</ArticleId><ArticleId IdType="pubmed">21422986</ArticleId></ArticleIdList></Reference><Reference><Citation>Gourlay AJ, Pharris AM, Noori T, Supervie V, Rosinska M, van Sighem A, et al. Towards standardized definitions for monitoring the continuum of HIV care in Europe. AIDS. 2017;31(15):2053-8. 10.1097/QAD.0000000000001597</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000001597</ArticleId><ArticleId IdType="pmc">PMC5603982</ArticleId><ArticleId IdType="pubmed">28906276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommen C, Commenges D, Vu SL, Meyer L, Alioum A. Estimation of the distribution of infection times using longitudinal serological markers of HIV: implications for the estimation of HIV incidence. Biometrics. 2011;67(2):467-75. 10.1111/j.1541-0420.2010.01473.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1541-0420.2010.01473.x</ArticleId><ArticleId IdType="pubmed">20731647</ArticleId></ArticleIdList></Reference><Reference><Citation>Giardina F, Romero-Severson EO, Axelsson M, Svedhem V, Leitner T, Britton T, et al. Getting more from heterogeneous HIV-1 surveillance data in a high immigration country: estimation of incidence and undiagnosed population size using multiple biomarkers. Int J Epidemiol. 2019;48(6):1795-803. 10.1093/ije/dyz100</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz100</ArticleId><ArticleId IdType="pmc">PMC6929534</ArticleId><ArticleId IdType="pubmed">31074780</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Severson EO, Lee Petrie C, Ionides E, Albert J, Leitner T. Trends of HIV-1 incidence with credible intervals in Sweden 2002-09 reconstructed using a dynamic model of within-patient IgG growth. Int J Epidemiol. 2015;44(3):998-1006. 10.1093/ije/dyv034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv034</ArticleId><ArticleId IdType="pmc">PMC4521128</ArticleId><ArticleId IdType="pubmed">26163684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren E, Romero-Severson E, Albert J, Leitner T. Combining biomarker and virus phylogenetic models improves HIV-1 epidemiological source identification. PLOS Comput Biol. 2022;18(8):e1009741. 10.1371/journal.pcbi.1009741</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009741</ArticleId><ArticleId IdType="pmc">PMC9455879</ArticleId><ArticleId IdType="pubmed">36026480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahiane SG, Eaton JW, Glaubius R, Case KK, Sabin KM, Marsh K. Updates to Spectrum’s case surveillance and vital registration tool for HIV estimates and projections. J Int AIDS Soc. 2021;24(Suppl 5) Suppl 5;e25777. 10.1002/jia2.25777</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jia2.25777</ArticleId><ArticleId IdType="pmc">PMC8454676</ArticleId><ArticleId IdType="pubmed">34546641</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Zhang F, Wand H. Using HIV diagnostic data to estimate HIV incidence: method and simulation. Stat Commun Infect Dis. 2011;3(1). 10.2202/1948-4690.1011</Citation><ArticleIdList><ArticleId IdType="doi">10.2202/1948-4690.1011</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control ECDC). HIV Platform tool. 2.0.0 ed. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/hiv-platform-tool
</Citation></Reference><Reference><Citation>Carlander C, Brännström J, Månsson F, Elvstam O, Albinsson P, Blom S, et al. Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden. BMJ Open. 2023;13(3):e069688. 10.1136/bmjopen-2022-069688</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-069688</ArticleId><ArticleId IdType="pmc">PMC10030896</ArticleId><ArticleId IdType="pubmed">36931676</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson E, Nakagawa F, van Sighem A, Axelsson M, Phillips AN, Sönnerborg A, et al. Challenges in modelling the proportion of undiagnosed HIV infections in Sweden. Euro Surveill. 2019;24(14):1800203. 10.2807/1560-7917.ES.2019.24.14.1800203</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2019.24.14.1800203</ArticleId><ArticleId IdType="pmc">PMC6462786</ArticleId><ArticleId IdType="pubmed">30968824</ArticleId></ArticleIdList></Reference><Reference><Citation>Brännström J, Sönnerborg A, Svedhem V, Neogi U, Marrone G. A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model. HIV Med. 2017;18(9):677-84. 10.1111/hiv.12509</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hiv.12509</ArticleId><ArticleId IdType="pubmed">28444865</ArticleId></ArticleIdList></Reference><Reference><Citation>Skar H, Axelsson M, Berggren I, Thalme A, Gyllensten K, Liitsola K, et al. Dynamics of two separate but linked HIV-1 CRF01_AE outbreaks among injection drug users in Stockholm, Sweden, and Helsinki, Finland. J Virol. 2011;85(1):510-8. 10.1128/JVI.01413-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01413-10</ArticleId><ArticleId IdType="pmc">PMC3014206</ArticleId><ArticleId IdType="pubmed">20962100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807. 10.1056/NEJMoa1506816</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1506816</ArticleId><ArticleId IdType="pmc">PMC4569751</ArticleId><ArticleId IdType="pubmed">26192873</ArticleId></ArticleIdList></Reference><Reference><Citation>Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-22. 10.1056/NEJMoa1507198</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1507198</ArticleId><ArticleId IdType="pubmed">26193126</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015. Available from: https://www.ncbi.nlm.nih.gov/books/NBK327115
</Citation><ArticleIdList><ArticleId IdType="pubmed">26598776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF. The first eight months of Sweden’s COVID-19 strategy and the key actions and actors that were involved. Acta Paediatr. 2020;109(12):2459-71. 10.1111/apa.15582</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15582</ArticleId><ArticleId IdType="pmc">PMC7537539</ArticleId><ArticleId IdType="pubmed">32951258</ArticleId></ArticleIdList></Reference><Reference><Citation>Teke Lloyd A, Sirkeci I. A long-term view of refugee flows from Ukraine: war, insecurities, and migration. Migrat Lett. 2022;19(4):523-35. 10.33182/ml.v19i4.2313</Citation><ArticleIdList><ArticleId IdType="doi">10.33182/ml.v19i4.2313</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakoya I, Álvarez-del Arco D, Woode-Owusu M, Monge S, Rivero-Montesdeoca Y, Delpech V, et al. A systematic review of post-migration acquisition of HIV among migrants from countries with generalised HIV epidemics living in Europe: mplications for effectively managing HIV prevention programmes and policy. BMC Public Health. 2015;15(1):561. 10.1186/s12889-015-1852-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-015-1852-9</ArticleId><ArticleId IdType="pmc">PMC4472169</ArticleId><ArticleId IdType="pubmed">26085030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kall M, Marcellin F, Harding R, Lazarus JV, Carrieri P. Patient-reported outcomes to enhance person-centred HIV care. Lancet HIV. 2020;7(1):e59-68. 10.1016/S2352-3018(19)30345-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(19)30345-5</ArticleId><ArticleId IdType="pubmed">31776101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>